Xilio Therapeutics (Nasdaq:XLO) granted non-qualified stock options to three new employees effective July 1, 2026, under its 2022 Inducement Stock Incentive Plan.
The grants cover 107,060 shares at an exercise price of $9.22 per share, with a ten-year term and time-based vesting, as an inducement under Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – XLO
-1.38%4.5x vol
2 alerts
-1.38%Session close to close
-3.3%Trough Tracked
$60.16MMarket Cap
4.5xRel. Volume
In the Jul 7 session, XLO declined 1.38%, reflecting a mild negative market reaction.
Argus tracked a trough of -3.3% from its starting point during tracking.
Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Trading volume was very high at 4.5x the daily average, suggesting heavy selling pressure.
The company issued non-qualified stock options for 107,060 shares at an exercise price matching the ...
Analysis
The company issued non-qualified stock options for 107,060 shares at an exercise price matching the market, under its inducement plan. These awards are routine hiring tools; investors may watch how frequently option and shelf capacities are tapped over time.
Key Figures
Inducement option grant size:107,060 sharesExercise price:$9.22 per shareOption term:10 years+5 more
8 metrics
Inducement option grant size107,060 sharesNon-qualified stock options granted to three new employees
Exercise price$9.22 per shareEqual to Xilio’s July 1, 2026 closing price
Option term10 yearsTen-year term for each stock option granted
Initial vesting tranche25% of sharesVests on first anniversary of employment commencement
Remaining vesting tranche75% of sharesVests in subsequent monthly installments
Monthly vesting schedule36 monthly installmentsRemainder vests over three years after first anniversary
New employees3 employeesRecipients of inducement stock option grants
Grant effective dateJuly 1, 2026Effective date of inducement stock option grants
Addition of a new director and related board composition changes.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent Xilio headlines covering governance, pipeline updates, and option grants have produced small, mixed share-price reactions without a consistent directional pattern.
"the company granted non-qualified stock options to purchase 107,060 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2026, the company granted non-qualified stock options to purchase 107,060 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
The stock options have an exercise price of $9.22 per share, which is equal to the closing price of the company’s common stock on July 1, 2026.Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to continued service with the company or any of its subsidiaries through each applicable vesting date.
The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
What stock options did Xilio Therapeutics (XLO) grant on July 1, 2026?
Xilio Therapeutics granted non-qualified stock options for 107,060 shares of common stock to three new employees. According to Xilio Therapeutics, these options were issued under the 2022 Inducement Stock Incentive Plan as employment inducements.
What is the exercise price of the new Xilio Therapeutics (XLO) inducement stock options?
The exercise price is $9.22 per share, equal to the closing price on July 1, 2026. According to Xilio Therapeutics, this pricing aligns the options’ value with the market price at the grant date.
How do the Xilio Therapeutics (XLO) inducement options vest for new employees?
The options vest 25% on the first anniversary of employment, then 75% in 36 equal monthly installments. According to Xilio Therapeutics, vesting requires continued service with the company or its subsidiaries through each vesting date.
What is the term of the Xilio Therapeutics (XLO) inducement stock options?
Each non-qualified stock option has a ten-year term from the grant date. According to Xilio Therapeutics, the options remain exercisable during this period, subject to vesting and standard plan and agreement conditions.
Why were these Xilio Therapeutics (XLO) stock options granted under Nasdaq Rule 5635(c)(4)?
The options were granted as an inducement material to new employees entering employment. According to Xilio Therapeutics, this structure complies with Nasdaq Listing Rule 5635(c)(4), which allows equity awards outside shareholder-approved plans for new hires.
Under which plan were the July 2026 Xilio Therapeutics (XLO) inducement options issued?
The options were issued under the 2022 Inducement Stock Incentive Plan. According to Xilio Therapeutics, the grants are also governed by individual stock option agreements detailing specific terms and conditions.
